Eight patients with a diagnosis of atherosclerotic heart disease and a history of typical angina pectoris, uncomplicated by cardiac dilatation or heart failure, were studied by means of standardized, symptom-limited treadmill exercise test. Repeatability of such testing was determined during two control tests 1-1.5 hours apart. From two to six days later, the same patients performed two treadmill tests after pulmonary and brachial arterial catheterization. The study design allowed evaluation of the effects of 0.005 mg/kg of ouabain at rest-both supine and standing-and during submaximal and maximal exercise.
Multistage treadmill exercise
Left ventricular dysfunction blood. Whether cardiac glycosides could improve function is controversial in view of the fact that they might exert a positive inotropic effect, further compromising an ischemic left ventricle. Some reports suggest improved left ventricular performance, whereas others show alleviation of angina or greater exercise capacity, or both, in some patients. [4] [5] [6] [7] [8] Although cardiac glycosides increase contractility of the left ventricle and improve function of dilated and failing heart, they do not increase myocardial efficiency in the nonfailing heart.9 Administration of digoxin fails to cause increase in either the duration of sustained isometric exercise or the maximal dynamic exercise in healthy men regardless of whether adequate time for recovery from prior stress is permitted. 10 This study was designed to observe possible acute effects of ouabain therapy in patients with angina pectoris uncomplicated by congestive heart failure, both at rest, whether supine or standing, and during exercise, whether submaximal or maximal. In addition to usual hemodynamic criteria at maximal performance, the ratio of mean systemic to mean pulmonary arterial pressure was suggestive of heart disease from other causes, e.g., hypertension. None was anemic or had evidence of pulmonary disease by chest X-ray and pulmonaryfunction screening tests. None had diabetes mellitus or was limited in exercise performance by intermittent claudication or skeleto-muscular disease. None of the patients had received any medication for at least two weeks preceding the study, with the exception of nitroglycerin which was discontinued on the days of the study.
All patients participated voluntarily, giving their informed consent after appropriate explanations. Seven had been participants in the rehabilitation program of the Cardio-Pulmonary Research Institute (CAPRI), where they exercised for at least one-half hour three times a week under medical supervision, but only three had been active for the past three months. The other four had been inactive; accordingly it was unrealistic to expect any significant physiologic changes from training.
The study design is shown in figure 1 . The durations of standing at rest before the measurements were the same and the timing of all other measurements was exactly the same in both tests. Supine measurements after Test 3 were taken as shown in figure 1 . Ouabain (0.005 mg/kg body weight) was injected 45 minutes after termination of Test 3, over a two-minute period, through the Swan-Ganz catheter that was then flushed with saline. This dosage of ouabain was equivalent to the "full digitalization" dosage by single intravenous injection of 0.25 to 0.50 mg of ouabain as listed by Goodman and Gilman. 13 After three more supine measurements ( fig. 1) 
Discussion
In general, the initial reproducibility of hemodynamic measurements was satisfactory, yet there was prolonged minor, but significant, relative tachyeardia with no clear explanation15 at rest after maximal exercise testing. Previous studies in normals showed the importance of dissipation of endogenous heat load when dynamic exercise was repeated within ten minutes,10 but the time interval allowed in this study design should have been ample to exclude any residual thermal effect. When retested after 1-1.5 hours, duration of such exercise tended to be longer in six of seven patients, and peak Vo, slightly exercise performance after treatment with lanatoside C of patients with angina pectoris in the absence of heart failure. Similarly, in normal men without heart disease, treatment with digoxin did not improve exercise capacity.10 Partial dis.agreement of our results with the findings of others who reported beneficial effects of treatment with cardiac glycosides in some patients with angina4' 7 8 may be attributed to differences in selection of patients and in type of exercise test and study protocol used.
In conclusion, the findings presented in this study of glycosides in other patients with angina pectoris that is complicated by cardiac dilatation and congestive heart failure.
